Comparison of IVIg and PLEX in patients with myasthenia gravis
暂无分享,去创建一个
[1] A. Engel. Myasthenia gravis and myasthenic disorders , 2012 .
[2] M. M. Winter,et al. Evidence-based guideline update: Plasmapheresis in neurologic disorders , 2011, Neurology.
[3] D. Sanders,et al. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity , 2009, The Lancet Neurology.
[4] Robert H. Paul,et al. Disease‐specific measure of quality of life for myasthenia gravis , 2008, Muscle & nerve.
[5] L. Zinman,et al. IVIG Treatment for Myasthenia Gravis , 2008, Annals of the New York Academy of Sciences.
[6] V. Bril,et al. A Comparison of the Effectiveness of Intravenous Immunoglobulin and Plasma Exchange as Preoperative Therapy of Myasthenia Gravis , 2008, Journal of clinical neuromuscular disease.
[7] L. Zinman,et al. IV immunoglobulin in patients with myasthenia gravis , 2007, Neurology.
[8] A. Vincent,et al. Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis , 2005, Current opinion in neurology.
[9] G. Samsa,et al. Quantitative myasthenia gravis score: Assessment of responsiveness and longitudinal validity , 2005, Neurology.
[10] John C. Keesey,et al. Clinical evaluation and management of myasthenia gravis , 2004, Muscle & nerve.
[11] A. Vincent,et al. Antibodies in Myasthenia Gravis and Related Disorders , 2003, Annals of the New York Academy of Sciences.
[12] S. Chevret,et al. Plasma exchange for generalised myasthenia gravis , 2002 .
[13] G. Parry,et al. Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis , 2002, Muscle & nerve.
[14] S. Vorstrup,et al. Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis. , 2001, Artificial organs.
[15] R. Barohn,et al. Myasthenia gravis , 2000, Neurology.
[16] R. Barohn,et al. Myasthenia gravis: recommendations for clinical research standards1 , 2000 .
[17] J. Howard. Intravenous Immunoglobulin for the Treatment of Acquired Myasthenia Gravis , 1998, Neurology.
[18] R. Barohn,et al. Reliability Testing of the Quantitative Myasthenia Gravis Score a , 1998, Annals of the New York Academy of Sciences.
[19] S. Chevret,et al. Clinical trial of plasma exchange and high‐dose intravenous immunoglobulin in myasthenia gravis , 1997 .
[20] D. Kiprov,et al. Myasthenic Crisis: Response to Plasmapheresis Following Failure of Intravenous γ-Globulin , 1993 .
[21] R. Lisak. Plasma exchange in neurologic diseases. , 1984, Archives of neurology.
[22] J. Raphael,et al. [Long-term effects of plasma exchange in myasthenia. Results of a randomized study]. , 1983, Presse medicale.
[23] J. Schwartz. Evidence-based guideline update: plasmapheresis in neurologic disorders. , 2011, Neurology.
[24] M. Mcquillen. Evidence-based guideline update: plasmapheresis in neurologic disorders. , 2011, Neurology.
[25] R. Hohlfeld,et al. The immunopathogenesis of myasthenia gravis. , 2008, Handbook of clinical neurology.
[26] S. Chevret,et al. Intravenous immunoglobulin for myasthenia gravis. , 2003, The Cochrane database of systematic reviews.
[27] S. Chevret,et al. Plasma exchange for myasthenia gravis. , 2002, The Cochrane database of systematic reviews.
[28] D. Kiprov,et al. Myasthenic crisis. Response to plasmapheresis following failure of intravenous gamma-globulin. , 1993, Archives of neurology.